Despite numerous studies confirming the long-acting pro-inflammatory role of CX3CL1-CX3CR1 in cardiovascular disease (26, 27), and the antagonist of CX3CR1 having been subjected to preliminary clinical translation (28, 29), considering the recently demonstrated protective role of this axis in neurodegenerative disease (30), a large number of in vitro experiments are still in need for subsequent validation. This evidence concerns the gene CX3CR1 and neurodegenerative disease.